Compare PFX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | NTRB |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 71.7M |
| IPO Year | N/A | N/A |
| Metric | PFX | NTRB |
|---|---|---|
| Price | $44.33 | $4.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 1.1K | ★ 23.0K |
| Earning Date | 12-12-2025 | 12-11-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | ★ $25,262,322.00 | $2,278,321.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | $21.09 | ★ N/A |
| Revenue Growth | ★ 13.89 | 12.69 |
| 52 Week Low | $41.00 | $3.72 |
| 52 Week High | $57.40 | $11.78 |
| Indicator | PFX | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 40.95 |
| Support Level | $41.50 | $4.60 |
| Resistance Level | $42.00 | $5.45 |
| Average True Range (ATR) | 0.60 | 0.37 |
| MACD | 0.28 | 0.09 |
| Stochastic Oscillator | 100.00 | 43.86 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.